Huahai Pharmaceutical announced on October 7 that it expects net profit attributable to the parent for the first three quarters of 2026 to be between 1.028 billion yuan and 1.103 billion yuan, an increase of about 648 million yuan to 723 million yuan compared with the same period last year, representing growth of about 170% to 190%. After deducting non-recurring gains and losses, net profit attributable to the parent is expected to be between 662 million yuan and 743 million yuan, up about 145% to 175% year on year. The announcement said the profit growth mainly came from market expansion in the active pharmaceutical ingredients business, increased market share in the domestic finished formulations business under centralized procurement policies, and improved operations in the US finished formulations business. Research and development optimization and the advancement of innovative drug products also provided support. The gain from disposing of a 67% stake in subsidiary Huahai Tianheng Shanghai Pharmaceutical Research during the reporting period also had a positive impact on profit. In the first half of 2026, Huahai Pharmaceutical achieved revenue of 4.913 billion yuan and net profit attributable to the parent of 771 million yuan.
Zhejiang Huahai Pharmaceutical Co LtdExpects Q1–Q3 net profit attributable to parent to rise 170%–190% year on year, driven by API market expansion, procurement share gains, US formulations improvement, and a subsidiary stake disposal gain.
